Gary Glick gets $27M to leap back in­to im­muno-on­col­o­gy R&D with No­var­tis, At­las and Abing­worth in his cor­ner


Gary Glick didn’t specif­i­cal­ly in­tend to start a new biotech af­ter he left Lyc­era, where he was the founder and CSO, a lit­tle more than a year ago. To hear him tell it, he wasn’t ex­act­ly sure what the next step in his ca­reer would be. But af­ter start­ing out talk­ing to some of the part­ners at At­las Ven­ture, tak­ing the helm of a new com­pa­ny al­most be­came in­evitable.

“By the end of the sum­mer (2015), we were talk­ing one day about var­i­ous ideas,” Glick re­calls. He put to­geth­er some slides, pick­ing up on some of the re­search that had been put in­to the in­nate im­mune sys­tem, a field he was in­ti­mate­ly aware of af­ter tack­ling the adap­tive side of the im­mune sys­tem at Lyc­era.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.